Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia

Evolus, Inc. (NASDAQ: EOLS), a leading performance beauty company specializing in aesthetic solutions, has announced its entry into the Australian market with the launch of Nuceiva® (prabotulinumtoxinA). This marks a significant step in Evolus’ global expansion strategy, establishing a strong foothold in a key international region.

“We are excited to launch Evolus in Australia, a pivotal moment in our global growth strategy. This expansion positions us for continued above-market growth and solidifies our status as a global leader in the aesthetics industry,” said David Moatazedi, President and Chief Executive Officer of Evolus.

Nuceiva® has received approval from the Therapeutic Goods Administration (TGA) for the temporary improvement of moderate to severe glabellar lines in adult patients.

Evolus has set up a direct operating entity in Australia, led by Daniel Henry, to collaborate closely with aesthetics professionals and offer Nuceiva® to patients. The device is known in the United States as Jeuveau® and has been the fastest-growing neurotoxin there for three consecutive years.

Dan Stewart, Vice President and General Manager of Evolus International, emphasized, “As the beauty and healthcare landscape evolves, our focus remains on partnering with customers and stakeholders to navigate these changes effectively. With Daniel Henry’s extensive experience and vision, we are committed to delivering exceptional service, innovative education, and a seamless online platform to support Australian practitioners and enhance patient satisfaction.”

Dr. Steven Liew, a renowned Plastic Surgeon and Medical Director at Shape Clinic in Sydney, expressed enthusiasm about the launch: “The evolving beauty scene in Australia, particularly among younger generations, reflects a growing interest in non-surgical enhancement. I’m excited to collaborate with Evolus as they introduce their unique offerings to the Australian market, providing practitioners with new options to meet diverse patient needs.”

Nuceiva®’s safety and efficacy have been demonstrated through the TRANSPARENCY clinical program, which includes three Phase III trials and the largest head-to-head aesthetic pivotal study versus Botox® (onabotulinumtoxinA) to date. For a full list of adverse events and contraindications, consult the Nuceiva® Prescribing Information.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is an innovative global beauty company focused on advancing the aesthetic neurotoxin market with its flagship product, Jeuveau® (prabotulinumtoxinA-xvfs). The company’s unique, customer-centric approach and advanced digital platform aim to set new standards in the beauty industry. Evolus is expanding its portfolio and has entered into agreements to distribute Evolysse™ and Estyme® dermal fillers. For more information, visit www.evolus.com and follow Evolus on LinkedIn, X, Instagram, and Facebook.

Forward-Looking Statements

This press release includes forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements, which relate to regulatory processes, future plans, and performance, involve risks and uncertainties. Factors that could cause actual results to differ include regulatory challenges, market dynamics, and the impact of COVID-19. For more details, see Evolus’ filings with the Securities and Exchange Commission at www.sec.gov. Evolus undertakes no obligation to update forward-looking statements except as required by law.

Source link

Share your love

Newsletter Updates

Enter your email address below and subscribe to our newsletter